Biogen shares fell Friday after the head of the FDA called for an investigation into the recent approval of the company’s Alzheimer’s drug, Aduhelm.
Biogen shares fell on Friday after the head of the Food and Drug Administration called for an investigation into the recent approval of the company’s Alzheimer’s drug, Aduhelm. Acting FDA Commissioner Dr. Janet Woodcock asked the Office of the Inspector General to investigate interactions between the U.S. agency and Biogen representatives prior to the drug’s approval on June 7. « I believe that it is critical that the events at issue be reviewed by an independent body such as the Office of the Inspector General in order to determine whether any interactions that occurred between Biogen and FDA review staff were inconsistent with FDA policies and procedures, » Woodcock wrote in a letter sent Friday. Shares of Biogen fell by more than 3% after the announcement. Biogen’s stock surged last month after the FDA approved the biotech company’s drug, the first medication cleared by U.
